BRAFwild papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors.

BRAFwild papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors.

Head Neck. 2018 Mar 23;:

Authors: Kim HK, Lee I, Lee J, Chang HS, Soh EY, Park IS, Kim JH, Rho YS, Lee DJ

Abstract
BACKGROUND: Using a large set of genomic data from The Cancer Genome Atlas (TCGA), we classified BRAFwild papillary thyroid carcinomas (PTCs) into 2 subtypes with distinct molecular patterns and different clinical behaviors. We also suggested gene signatures (RAS-score) to predict molecular subtypes and clinical behaviors of BRAFwild PTC.
METHOD: Integrated genomic analysis was done using all genomic data of PTC in TCGA data portal (https://ift.tt/2ilZJpU) and cancer browser (https://ift.tt/1D13VRx). Using Gene Ontology and a logistic regression test, we selected gene signatures (RAS-score) and applied this prediction model to the validation cohort (GSE60542).
RESULT: When we performed multiplatform genomic analysis, BRAFwild PTCs were divided into 2 molecular subtypes. Each subtype showed distinct molecular patterns and clinical behaviors. Gene signatures successfully predicted molecular subtype in another validation cohort.
CONCLUSION: We found that BRAFwild PTCs were divided into 2 molecular subtypes and each subtype showed distinct molecular patterns, different activated pathways, and different clinical behaviors.

PMID: 29573027 [PubMed - as supplied by publisher]

https://ift.tt/2pEJOaq